Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis
Authors:
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 12 (3) , 728-733
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)The American Journal of Cardiology, 2015
- Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trialsThe Lancet, 2015
- Statins and Cataracts—a Visual InsightCurrent Atherosclerosis Reports, 2014
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and AtherosclerosisJACC, 2013
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract ratJournal of Clinical Investigation, 2006
- Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.British Journal of Ophthalmology, 1995
- Lovastatin and the Human Lens; Results of a Two Year StudyOptometry and Vision Science, 1993
- Expanded clinical evaluation of lovastatin (EXCEL) study results II. Assessment of the human lens after 48 weeks of treatment with lovastatinThe American Journal of Cardiology, 1991
- Lovastatin (Mevinolin) in the Treatment of Heterozygous Familial HypercholesterolemiaAnnals of Internal Medicine, 1987